06:10 AM EDT, 04/08/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday that a phase 2 study evaluating the investigational drug zilebesiran in treating hypertension has met its primary endpoint. Zilebesiran reached the study's primary endpoint after demonstrating statistically significant reductions in systolic blood pressure in three months, the company said. Most laboratory abnormalities of interest were mild,...

WASHINGTON (Reuters) - Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters. Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants,...

06:05 AM EDT, 04/08/2024 (MT Newswires) -- A full solar eclipse on Monday will briefly obscure sunlight to utility-scale solar generation facilities from Texas through Maine with a combined 6.5 gigawatts of capacity, the US Energy Information Administration reported Friday. The eclipse will also partially block sunlight to facilities with a combined 84.8 GW of capacity in a larger swath...

(Reuters) - Google parent Alphabet's contemplated acquisition of marketing software company HubSpot ( HUBS ) would likely spark opposition from regulators even as many experts agree it would not curb competition, and would require the technology giant to open a new front in its battle with antitrust watchdogs. Reuters reported last week that Google was mulling an offer for HubSpot...